Synopsis

In vivo imaging has become an integral part of pharmaceutical research, and MRI with its great flexibility is an important player. At the preclinical level, extensive validation of imaging readouts against established techniques, such as fluid biomarkers, histology, or immunohistochemistry, precedes their adoption in pharmacological studies. These often involve a large number of animals, as several compound doses or therapies are compared. Through examples this presentation aims to illustrate possible ways to address the challenges of preclinical MRI in the assessment of reproducible, well-validated readouts while achieving a throughput that is compatible with complex dosing schedules in pharmacological studies.

Acknowledgements

References